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Abstract
Background: Adjuvant! Online is a web-based application designed to provide 10 years survival probability of patients with
breast cancer. Several predictors have not been assessed in the original Adjuvant! Online study. We provide the validation of
Adjuvant! Online algorithm on two breast cancer datasets, and we determined whether the accuracy of Adjuvant! Online is
improved with other well-known prognostic factors.
Patients and Methods: The French data set is composed of 456 women with early breast cancer. The Dutch data set is
composed of 295 women less than 52 years of age. Agreement between observation and Adjuvant! Online prediction was
checked, and logistic models were performed to estimate the prognostic information added by risk factors to Adjuvant!
Online prediction.
Results: Adjuvant! Online prediction was overall well-calibrated in the French data set but failed in some subgroups of such
high grade and HER2 positive patients. HER2 status, Mitotic Index and Ki67 added significant information to Adjuvant!
Online prediction. In the Dutch data set, the overall 10-year survival was overestimated by Adjuvant! Online, particularly in
patients less than 40 years old.
Conclusion: Adjuvant! Online needs to be updated to adjust overoptimistic results in young and high grade patients, and
should consider new predictors such as Ki67, HER2 and Mitotic Index.
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Introduction
Breast cancer prognosis determination relies upon pathological
features able to classify breast cancer in subgroups of similar
behavior. Tumour size, axillary lymph node involvement, grade as
defined by Elston & Ellis, Estrogen Receptor (ER) status,
Progesterone Receptor (PR) status and HER2 status are routine
determinants of the breast cancer prognosis. To improve the
ability to accurately predict the prognosis of breast cancer patients
and the likely benefit of adjuvant systemic therapy, combinations
of several clinicopathological prognostic factors have been tailored
for clinical decision making. Nottingham Prognosis Index (NPI) is
based on the Tumour Size, Tumour Grade and Lymph Node
Involvement [NPI=Grade+Node+0.2*Size] [1,2,3]. More recent-
ly Ravdin et al [4] built a web based application able to provide 10
years survival and relapse probability of an individual patient
(www.adjuvantonline.com). This index is derived from women 35
to 59 years old at diagnosis and treated between 1988 and 1992 of
the US SEER (Surveillance, Epidemiology, End-Results data and
estimates) registry which includes around 10% of all US breast
cancer patients. The calculation process is based on actuarial
analysis using age at diagnosis, comorbidity factors, ER, tumour
size, tumour grade and lymph node status as input. The program
gives the estimated prognosis, but also the expected benefit of
several therapeutic options in a comprehensive format, adapted for
decision making. Estimates of the efficacy of adjuvant hormonal
therapy and chemotherapy are based mainly on the proportional
risk reduction reported by Early Breast Cancer Trialists
Collaborative Group meta-analyses [5,6,7].
Although Adjuvant! Online is increasingly being used by
physicians[8], few validation studies from different countries with
very different patient and tumour patterns have been published
[9,10,11,12]. Some limitations have been underlined in these
studies, including 1) Adjuvant! Online’s prediction were on the
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27446whole overoptimistic on a UK population; 2) Young age seems to
be a category with constant overestimated probability; 3) Relapse
free survival estimation, based on extrapolation, seems to be
unreliable.
Finally, several predictors such as HER2 over expression status,
proliferation markers or gene expression signatures [13] have not
been assessed in the original Adjuvant! Online study. Although
these prognostic factors are more and more introduced into
clinical practice, no validation study has evaluated the perfor-
mance of Adjuvant! Online algorithm among subgroups defined
with these variables.
The aim of this study was to validate Adjuvant! Online
algorithm on two breast cancer datasets collected from two large
European comprehensive cancer centres, and to determine
whether the accuracy of Adjuvant! Online could be improved by
the use of several well-known prognostic factors not used in
current calculations for the prediction of 10- year overall
survival.
Materials and Methods
Ethics Statement
The registration of patients of the Institut Curie in this cohort
received a favorable agreement of the french National Committee
on Computers and Liberties (CNIL, Commission nationale de
l’informatique et des liberte ´s). Patients gave informed written
consent prior to be registered in the cohort. The study was
approved by the breast cancer study group of the Institut Curie.
Dutch study was approved by the medical-ethics committee of the
Netherlands Cancer Institute.
Patients
French data set. The French population is an original data
set composed of 456 women treated at the Institut Curie between
1995 and 1996. This data set was firstly collated to validate the
Ki67 rate and other factors prognostic value in a larger cohort of
early-stage breast cancer patients. Inclusion criteria were early
Table 1. Baseline characteristics, French and Dutch population.
French data set Dutch data set
N (%) N (%) P
All patients 435 (100) 247 (100)
Age (years) 54.6 (8.42)
a 43.7 (5.5)
a ,0.01
,40 16 (3.7) 57 (23.1)
$40 419 (96.3) 190 (76.9)
Oestrogen-receptor status Positive 367 (84.4) 176 (71.3) ,0.01
Negative 68 (15.6) 71 (28.7)
Histology Ductal carcinoma 340 (78.2) 233 (94.3) ,0.01
Lobular carcinoma 63 (14.4) 10 (4.0)
Other 32 (7.4) 4 (1.6)
Tumour size (mm) #20 328 (75.4) 124 (50.2) ,0.01
.20 107 (24.6) 123 (49.8)
Grade 1 156 (35.9) 44 (17.8) ,0.01
2 182 (41.8) 81 (32.8)
3 97 (22.3) 122 (49.4)
N Positive 0 (0) 120 (48.6) ,0.01
Negative 435 (100) 127 (51.4)
HER2 Positive 23 (5.3) 47 (20.6) ,0.01
Negative 412 (94.7) 181 (79.4)
Treatment None 377 (86.7) 139 (56.3) ,0.01
Chemotherapy 28 (6.4) 79 (32.0)
Hormonotherapy 30 (6.9) 14 (5.7)
Both 0 (0) 15 (6.1)
Mastectomy No 435 (100) 140 (56.7) ,0.01
Yes 0 (0) 107 (43.3)
Mitotic index 1 298 (68.5) 95 (38.5) ,0.01
2 53 (12.2) 38 (15.4)
3 84 (19.3) 114 (46.2)
KI67 #20 262 (49.9) -
.20 173 (50.1) -
Genomic signature Negative - 155 (62.8)
Positive - 92 (37.2)
amean (sd).
doi:10.1371/journal.pone.0027446.t001
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by conservative surgery and radiotherapy. None of these patients
received neoadjuvant treatment (chemotherapy, hormonotherapy
or radiotherapy). The clinical data were extracted from medical
records of the Institut Curie prospective breast cancer database.
Histological features (histological type, histological grade as
defined by Elston & Ellis, Mitotic Index, Ki67 staining, ER
status, PR status, HER2 over-expression status) were re-assessed
for each sample by pathologists of the Institut Curie. Mitotic Index
(MI) was defined by the number of mitoses observed in 10
successive high power fields using a microscope with a 40x/0.7
objectives and a 10x ocular. Mitotic Index was assessed on
histological sections stained by Hematein, Eosin and Saffron. Van
Diest and al’s criteria [14] were used to define mitotic figures.
Ki67 (Clone MIB1,Dako A/S, Glostrup, Denmark) immun-
ostaining was performed. Semiquantitative assessment was
performed by estimating at X200 magnification, the percentage
of positive neoplastic nuclei within the area of highest positivity
chosen after scanning the entire tumour surface at low power (x10
objective). All nuclei with homogeneous staining, even with a light
staining or only a nucleolar staining, were interpreted as positive.
ER (clone 6F11, Novocastra, 1/200), PR (clone 1A6, Novocastra,
1/200) immunostaining were performed as previously described.
Cases were considered positive for ER and PR according to
standardised guidelines using $10% of positive nuclei per
carcinomatous cells. HER2 overexpression status was determined
according to American Society of Clinical Oncology (ASCO)
guidelines [15].
Dutch data set [16]. Tumors from a series of 295
consecutive women with breast cancer were selected from the
fresh-frozen–tissue bank of the Netherlands Cancer Institute
according to the following criteria: the tumor was primary
invasive breast carcinoma that was less than 5 cm in diameter at
pathological examination (pT1 or pT2); without involvement of
the apical axillary lymph nodes; the age at diagnosis was 52 years
or younger; the calendar year of diagnosis was between 1984 and
1995; and there was no previous history of cancer, except non-
melanoma skin cancer. In the original study, this population was
used to validate the prognostic value of a 70-gene expression
profile. All patients had been treated by modified radical
mastectomy or breast-conserving surgery, including dissection of
the axillary lymph nodes, followed by radiotherapy if indicated.
Follow-up information was extracted from the medical registry of
the Netherlands Cancer Institute. Formalin-fixed, paraffin
embedded tumour tissue was used to evaluate the following:
tumour type, histological grade, Mitotic Index, ER status, HER2
status.
In both data sets, Adjuvant! Online version 8.0 was used to
compute 10-years survival probability.
Statistics
All computations were done separately on French and Dutch
data sets. Analysis included two stages. First, we checked the
agreement between observed and Adjuvant! Online predicted 10-
years survival, and secondly, to what extent each prognostic factor
adds some information to Adjuvant! Online prediction.
Agreement between observed 10-years survival and
Adjuvant! Online predicted 10-years survival. Average
Adjuvant! Online predicted 10-years survival and observed 10-
years survival were computed globally and for several subgroups of
patients defined from major prognostic factors in breast cancer.
Calibration between observed and mean predicted outcome was
evaluated using the Cox method [17]. This method tests the
agreement between a sequence of binary responses Yi (i.e. 10-year
observed survival yes=1 or no=0, for each patient i) and a set of
corresponding probabilities pi (ie Adjuvant! Online 10-year
predicted survival probability), by fitting a simple logistic model
without intercept: log(P(Yi=1)/P(Yi=0))=a+b log(pi/(12pi)),
and testing the null hypothesis that intercept a is equal to 0 and
b is equal to 1, corresponding to a well calibrated model.
Performance of Adjuvant! Online and other
predictors. If a lack of agreement between observation and
prediction is detected in some specific subgroups, some variables
were tested as to whether they would add prognostic information
to Adjuvant! Online. Variables already used in Adjuvant! Online
algorithm and variables not used in Adjuvant! Online algorithm
were evaluated in two separated analyses. To perform these two
analyses, we used a method derived from Bleeker et al [18] to test
the contribution of each factor to Adjuvant! Online prediction: a
logistic regression model was performed including Adjuvant!
Online survival prediction as an offset variable, i.e. with a
parameter estimate constrained to 1. This analysis allows
estimating the regression coefficient b of a variable Xi taking
into account AdjvuvantOnline a priori known component by
including pi in the linear predictor during fitting: log(P(Yi=1)/
P(Yi=0))=a+bXi+log(pi/(12pi)). Since the parameter of the offset
variable is equal to 1, Adjuvant! Online prognostic value is not re-
estimated in the model.
Variables already used by Adjuvant! Online for 10-year survival
prediction (i.e. age at diagnosis, ER status, tumour size, tumour
grade, lymph node status and treatment type) were included
together in a multivariate model with Adjuvant! Online prediction
offset. In this model, a significant coefficient means that the
association of a predictor with the outcome in the validation
population differs from the original population [18].
Figure 1. Mean predicted versus observed survival. French
population. The data were divided into 5% intervals for the predicted
values. Observed percentages were calculated for each interval subset
and were plotted against the average predicted values. The grey thin
line of slope=1 and intercept=0 corresponds to a perfect agreement
between observed and predicted values.
doi:10.1371/journal.pone.0027446.g001
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(histologic type, HER2 status, mastectomy, Mitotic Index, KI67
and gene-expression signature if available) were included sepa-
rately in an univariate model only with Adjuvant! Online
prediction offset. In this analysis, a significant coefficient means
that a predictor adds some information to Adjuvant! Online
original model.
The gain in predictive inaccuracy of models including variables
not used in Adjuvant! Online algorithm, as compared with model
with Adjuvant! Online prediction alone, was investigated using the
method of Schemper [19]. Reyal and colleagues have recently
used this approach in the context of gene signatures [20].
Predictive inaccuracy is calculated as the average of the absolute
difference between observed outcomes and model predictions.
Explained variations were also computed and represent a measure
equivalent to R2 in linear regression. Standard errors were
obtained by bootstrapping 200 resamples. Areas under the curve
(AUC) were also computed.
Significance was defined as p,0.05 (two-sided). Statistical
analyses were performed using R 2.12.1 software (http://www.
R-project.org).
Results
Baseline characteristics
French data set. 10-years survival status was unknown for 21
patients. Four hundred and thirty five (435) out of 456 patients
were included in the analysis. Patients included in the analysis
were compared to those not included; no statistically significant
difference was observed between this two groups.
Patients’ clinico-pathological characteristics are shown in Table 1.
Mean age was 55 years old (68.4) at time of diagnosis. The majority of
patients had an invasive ductal carcinoma (78%), a T1 tumor (76%),
Elston Ellis grade 1 (36%) or grade 2 tumours (42%) and received no
adjuvant systemic treatment nor hormonal therapy (87%).
Dutch data set. 10-year survival status was unknown for 48
patients. 247 out of 295 patients were included in the analysis.
Patients included in the analysis were more likely to have negative
ER and grade III tumors.
Dutch patients were younger than the French (4465.5 years),
and tumors showed more aggressive features: 50% had T2 tumors,
and 49% had grade III tumors. More than 35% of patients had
undergone chemotherapy.
Table 2. Adjuvant! Predicted versus observed 10 years survival.
Agreement evaluation
Predicted survival
a Observed survival
a Predicted - Observed P
All patients 85.1 87.4 22.3 0.35
Adjuvant! Online predictors Age (years) ,40 89.5 75.0 14.5 0.22
$40 84.9 87.8 22.9 0.21
Estrogen receptor status Positive 86.3 89.6 23.3 0.14
Negative 78.5 75.0 3.5 0.18
Tumour size (mm) #20 87.9 89.6 21.7 0.60
.20 76.5 80.4 23.9 0.58
Grade 1 89.9 94.2 24.3 0.14
2 84.7 89.6 24.9 0.09
3 77.9 72.2 5.7 0.02
Treatment None 85.4 89.9 24.5 0.02
Chemotherapy 81.4 71.4 10 ,0.01
Hormonotherapy 84.4 70.0 14.4 0.04
Both
Other predictors Histology Ductal carcinoma 84.7 87.1 22.4 0.37
Lobular carcinoma 86.3 87.3 21 0.85
Other 86.2 90.6 24.4 0.70
HER2 Positive 82.7 69.6 13.1 0.07
Negative 85.2 88.4 23.2 0.16
Mitotic index 1 84.4 92.6 28.2 0.01
2 83.9 79.2 4.7 0.30
3 77.5 73.8 3.7 0.19
KI67 ,20 87.4 92.7 25.3 0.01
$20 81.5 79.2 2.3 0.06
French population.
aPercentage.
doi:10.1371/journal.pone.0027446.t002
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French data set. The overall 10-year survival of the French
population was very close to the Adjuvant! Online predicted
survival (87% vs. 85%). Figure 1 shows the observed versus the
average predicted outcomes in the overall French population.
Adjuvant! Online was globally well calibrated. Observed and
predicted outcomes did not differ regardless patients’ predicted
prognoses (p=0.35). However, a subgroup analysis highlighted
some weaknesses in the performance of Adjuvant! Online
prediction in, for instance, high grade, Ki67,20 and
chemotherapy treated tumors subgroups (Table 2). 10-year
survival in patients younger than 40 years old was overestimated
by Adjuvant! Online, but the difference was not significant (75%
vs. 90%, p=0.22).
Variables significantly associated with 10-year survival were
Elston Ellis grade, HER2 over expression status, Mitotic Index and
Ki67 index (data not shown). Taking into account Adjuvant!
Online information as an offset in the logistic regression model,
grade became non significant (Table 3). HER2 status, Mitotic
Index, Ki67 and treatment type were strongly associated with 10-
year survival, even considering this Adjuvant! Online a priori
information.
Dutch data set. The overall 10-year survival was
overestimated by Adjuvant! Online and observed and predicted
outcome differed significantly (66% vs. 79% p=0.00001)
(Table 4, Figure 2). This difference was mainly due to age:
the larger difference between prediction and observation was
observed for the subgroup of patients younger than 40 years old at
diagnosis (75.7% vs. 45.6%, p,0.01). Age at diagnosis, Elston Ellis
grade, HER2 status, Mitotic Index, and 70-genes signature were
significantly associated with 10-years survival (data not shown).
Only age, Mitotic Index and 70-genes signature remained
significant when analyzed with Adjuvant! Online information as
offset in the logistic regression model (Table 5).
Predictive accuracy
The gain in predictive accuracy from adding each variable not
used in Adjuvant! Online algorithm is presented in Table 6 and
Table 7. In the French data set, the largest decrease in predictive
inaccuracy is seen with Mitotic Index, following with Ki67 and
HER2 over expression (3.3%, 2.4% and 1.2% in term of explained
variation, respectively). Values for explained variation are higher
in the Dutch data set, particularly for 70-genes signature (13.1%)
and Mitotic Index (6.7%). Results were similar in term of gain of
area under the curve.
Table 3. Odds ratio taking into accout Adjuvant Online! a priori information.
Predictor evaluation
OR
a [CI 95%] P
Adjuvant! Online predictors
b Age (years) ,40 1 0.12
$40 3.26 [ 0.82; 13.05 ]
Estrogen receptor status Positive 1 0.69
Negative 0.85 [ 0.37; 1.92 ]
Tumour size (mm) #20 1 0.33
.20 1.37 [ 0.72; 2.63 ]
Grade 1 1 0.18
2 0.91 [ 0.39; 2.12 ]
3 0.48 [ 0.19; 1.21 ]
Treatment None 1 0.02
Chemotherapy 0.66 [ 0.22; 1.98 ]
Hormonotherapy 0.27 [ 0.11; 0.66 ]
Both
Other predictors
c Histology Ductal carcinoma 1 0.86
Lobular carcinoma 0.89 [ 0.39; 2.02 ]
Other 1.31 [ 0.37; 4.7 ]
HER2 Positive 1 0.04
Negative 2.98 [ 1.12; 7.95 ]
Mitotic index 1 1 0.02
2 0.39 [ 0.17; 0.88 ]
3 0.44 [ 0.23; 0.86 ]
KI67 ,20 1 0.01
$20 0.46 [ 0.25; 0.84 ]
French population.
aassociated odds ratio taking into account Adjuvant! prediction.
bmultivariate estimation.
cunivariate estimation.
doi:10.1371/journal.pone.0027446.t003
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Using two independent and very different data sets, this study
focused on evaluation of the 10-year survival prediction perfor-
mance of Adjuvant! Online. The French dataset was composed of
patients with an early stage breast carcinoma with no axillary
lymph node involvement. Few patients received an adjuvant
systemic treatment. The Dutch Dataset was previously published
as the validation study of the 70-genes molecular signatures. It was
composed of patients younger than 52 years old and a significant
over-representation of patients with aggressive features (young age,
high grade, HER2 positive, ER negative) was identified when
compared to the French Dataset. We showed that the calibration
of Adjuvant! Online was overall satisfactory in the French data set,
but failed in some subgroups of patients, particularly among those
with the most aggressive prognostic factors (young age, high grade
and HER2 positive patients). In the Dutch data set, Adjuvant!
Online prediction was highly overoptimistic.
The 10-year survival estimation error in the subgroup of the
youngest patients was already highlighted in three other large
calibration studies [9,10,11]. In the French data set, 10-year
survival of patients younger than 40 years old was overestimated
by Adjuvant! Online, and the difference was significant. The
difference was more obvious in the Dutch validation set that
included only patients younger than 52 years old. 23% of them
were younger than 40 years old. Consequently, outcome
prediction in this subgroup of patients should be interpreted
carefully in the Dutch population: the weak calibration of
Adjuvant! Online was identified in almost all subgroups and could
be explained by the over-representation of young patients in the
overall population. Our discussion will therefore mainly focus on
results based on the French data set, since Adjuvant! Online
calibration was overall correct.
Adjuvant! Online survival estimation was restricted to women in
the SEER registry from 35 to 59 years of age at diagnosis [4].
Prediction for patients younger that 35 or older than 59 relies
mostly on approximations. Although these subgroups have small
sample size, Figure 3 showed that predictions were overoptimistic
in two validation study [9,11]. Some adjustments can be done
using the prognostic factor impact calculator integrated in the
Adjuvant! Online tool [4,9], but the manual agreement obtained
Table 4. Adjuvant! Predicted versus observed 10 years survival.
Agreement evaluation
Predicted survival
a Observed survival
a Predicted - Observed P
All patients 78.6 66.4 12.2 ,0.01
Adjuvant! Online predictors Age (years) ,40 75.7 45.6 30.1 ,0.01
$40 79.5 72.6 6.9 0.06
Estrogen receptor status Positive 82.8 75.0 7.8 0.01
Negative 68.3 45.1 23.2 ,0.01
Tumour size (mm) #20 86.5 74.2 12.3 ,0.01
.20 70.6 58.5 12.1 0.01
N No 81.2 64.6 16.6 ,0.01
Yes 75.9 68.3 7.6 0.13
Grade 1 92.1 95.5 23.4 0.59
2 84.3 76.5 7.8 0.02
3 70.0 49.2 20.8 ,0.01
Treatment None 78.3 64.0 14.3 ,0.01
Chemotherapy 79.7 68.4 11.3 0.05
Hormonotherapy 71.5 64.3 7.2 0.41
Both 82.4 80.0 2.4 0.94
Other predictors Histology Ductal carcinoma 78.5 66.1 12.4 ,0.01
Lobular carcinoma 78.5 70.0 8.5 0.75
Other 85.2 75.0 10.2 0.31
Mastectomy No 81.1 70.7 10.4 ,0.01
Yes 75.4 60.7 14.7 ,0.01
HER2 Positive 72.3 51.1 21.2 ,0.01
Negative 79.7 69.1 10.6 ,0.01
Mitotic index 1 88.1 87.4 0.7 0.89
2 82.6 73.7 8.9 0.06
3 69.4 46.5 22.9 ,0.01
Signature Negative 75.3 51.0 24.3 ,0.01
Positive 84.3 92.4 28.1 0.04
Dutch population.
aPercentage.
doi:10.1371/journal.pone.0027446.t004
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In our opinion, this process does not meet the requirement of a
prognostic index in individual-based clinical practices because of
the lack of reproducibility between estimation. Specific model
should be designed in these subgroups, and Adjuvant! Online
predictions should only be computed and used for 35 to 59 years
old patients.
In the French data set, survival of patients with grade 3 tumors
seemed to be overestimated by Adjuvant! Online. Campbell et al
[9] found a similar result and even concluded that Adjuvant!
Online predictions were overoptimistic in almost all subgroups
analysis performed. In our study, the prognostic value of grade as
defined by Elston Ellis became non significant when taking into
account Adjuvant! Online a priori information. Thus, the global
effect of grade on 10-year survival seems to be captured by
Adjuvant! Online, but is underestimated in the subgroup of grade
3 tumors.
To our knowledge, our study is the first to evaluate the influence
of HER2 status, Ki67 and Mitotic Index on the performance of
Adjuvant! Online. In the French data set, Adjuvant! Online was
over optimistic in HER2 positive, Mitotic Index.1 or Ki67.20
patients. All three factors brought some statistically significant
prognostic information in addition to Adjuvant! Online. These
results are consistent with a recent finding from Lende et al [21]
showing that Mitotic Index is superior to Adjuvant! Online
guidelines in prognosticating patients with lymph-node negative
breast cancer younger than age 55 years. However, predictive
accuracy and AUC improvement when taking into account these
variables remained small. This was expected since the overall
calibration of Adjuvant! Online was correct. But the interest of
these variables should be considered in term of individual
prediction: the underestimation of mortality in the small subgroups
of HER2+ patients do not change a lot the global accuracy of the
model, but can have serious individual consequences, since these
estimations may be utilized by clinicians to change their
therapeutic attitude [8,22,23,24], besides other factors also taken
into consideration [24,25]. Financial implications should of course
be discussed, and the minor global improvement of Adjuvant!
Online performance could be considered too weak in term of cost-
effectiveness, given the scarcity of health care resources. On the
other hand, Adjuvant! Online is not necessarily the most cost-
effective tool currently available [26]. Moreover, HER2 [23] and
Mitotic Index are already used in clinical practices, and the use of
Ki67 measure should increase, since its prognostic value has been
confirmed in several studies, including univariate and multivariate
models [27]. Absence of HER2 overexpression. and low Ki67 may
also identify patients who obtain minimal benefit from adjuvant
chemotherapy [28].
Mitotic Index and Ki-67 are both proliferative biomarkers that
were correlated in early breast cancers treated with neoadjuvant
therapy [29]. Despite a slight advantage of Mitotic Index over
Ki67 in terms of improvement of the predictive inaccuracy of
Adjuvant! Online, this study was not enough powered to assert
that one factor is statistically better than one other, and if both add
independent prognostic information in a multivariate model.
Despite of the fact that results from Dutch population must be
interpreted with caution, it seems important to highlight that
genomic information could improve prediction accuracy in breast
cancer. Besides Amsterdam 70-gene prognostic signature [16],
several authors [30,31,32] have validated the independent
prognostic information brought by molecular characteristics of
the tumours, and emphasized the complementary nature of these
tools with more classical clinico-pathological features.
This study is not without limitations. First of all, Adjuvant!
Online was developed in the United States. As in Campbell et al
[9] British study conclusion, lack of agreement between observa-
tion and Adjuvant! Online prediction could come from a poor
external validity of Adjuvant! Online in French or Dutch
population, and could confirm the need for a state-specific
prediction model development. Using an American population,
the gap between observation and prediction results could be
potentially smaller. However, the prognostic value of HER2 status,
Ki67 and Mitotic Index are well documented in many publications
[33,34], and the growing use of these validated independent
prognostic factors in clinical practices should lead to consider them
as good candidate markers to improve the accuracy of actual
model.
Another weakness of this study is the small sample size of the
two validation sets, compared to other validation studies. When
the sample size is large, a classical approach is to group subjects
into sets with nearly constant predicted probability, and to
compare observed proportion with prediction in each set.
However, this method is not adapted for small sample size, since
it leads to very small sets. That is why we used the Cox approach,
specifically developed to test the calibration between observation
and prediction with small sample size [17].
The use of a Kaplan-Meı ¨er estimations and proportional hazard
models would have been more adapted to describe survival data,
like in other validation studies [9,10,11]. Nevertheless, the use of a
logistic model has a specific advantage: by introducing Adjuvant!
Online prediction as an offset into the model, this method allows
to test directly if a factor adds or not some prognostic information
to the current Adjuvant! Online prediction. Since Adjuvant!
Online tool only provides 10-year survival probabilities and does
not provide any coefficients of the underlying model used
Figure 2. Mean predicted versus observed survival. Dutch
population. The data were divided into 5% intervals for the predicted
values. Observed percentages were calculated for each interval subset
and were plotted against the average predicted values. The thin line of
slope=1 and intercept=0 corresponds to a perfect agreement
between observed and predicted values.
doi:10.1371/journal.pone.0027446.g002
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prediction in a survival model.
In conclusion, over optimistic results of Adjuvant! Online in
poor prognostic subgroups are problematic, since some therapeu-
tic decisions are based on Adjuvant! Online results. Adjuvant!
Online could therefore be updated to adjust biased predictions in
young and high grade subgroups of patients, and to consider
several other candidate markers, especially Ki67, HER2, and
Mitotic Index, known as independent risk factors in breast cancer.
These recommendations are based on the analyses of two
relatively small data sets, and should be validated in an
independent population.
Table 5. Odds ratio taking into accout Adjuvant Online! a priori information.
Predictor evaluation
OR
a [CI 95%] P
Adjuvant! Online predictors
b Age (years) ,40 1 0.01
$40 2.61 [ 1.31; 5.19 ]
Estrogen receptor status Positive 1 0.60
Negative 0.83 [ 0.42; 1.66 ]
Tumour size (mm) #20 1 0.09
.20 1.73 [ 0.92; 3.25 ]
N No 1 0.09
Yes 0.44 [ 0.17; 1.12 ]
Grade 1 1 0.08
2 0.33 [ 0.07; 1.50 ]
3 0.23 [ 0.05; 1.05 ]
Treatment None 1 0.55
Chemotherapy 0.48 [ 0.18; 1.29 ]
Hormonotherapy 0.68 [ 0.17; 2.75 ]
Both 0.64 [ 0.13; 3.16 ]
Other predictors
c Histology Ductal carcinoma 1 0.96
Lobular carcinoma 1.21 [ 0.28; 5.31 ]
Other 0.91 [ 0.07; 11.76 ]
Mastectomy No 1 0.61
Yes 0.86 [ 0.49; 1.52 ]
HER2 Positive 1 0.26
Negative 1.50 [ 0.75; 3.00 ]
Mitotic index 1 1 0.02
2 0.62 [ 0.24; 1.63 ]
3 0.38 [ 0.18; 0.79 ]
Signature Negative 1 ,0.01
Positive 8.21 [ 3.41; 19.72 ]
Dutch population.
aassociated odds ratio taking into account Adjuvant! prediction.
bmultivariate estimation.
cunivariate estimation.
doi:10.1371/journal.pone.0027446.t005
Table 6. Predictive inaccuracy, explained variation and area under curve for 10-years survival in the French dataset.
Predictive inaccuracy Explained variation (%) AUC
Model without predictors 0.21260.021 2 0.652 [0.575;0.728]
Model with histological type 0.21260.022 0.060.5 0.655 [0.579;0.731]
Model with HER2 0.21060.021 1.261.7 0.678 [0.606;0.750]
Model with mitotic index 0.20560.021 3.362.1 0.702 [0.633;0.771]
Model with KI67 0.20760.020 2.461.7 0.692 [0.625;0.760]
All models are estimated taking into account Adjuvant! Prediction as an offset.
doi:10.1371/journal.pone.0027446.t006
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27446Table 7. Predictive inaccuracy, explained variation and area under curve for 10-years survival in the Dutch dataset.
Predictive inaccuracy Explained variation (%) AUC
Model without predictors 0.39360.017 2 0.701 [0.634;0.769]
Model with histological type 0.39360.017 0.060.5 0.701 [0.634;0.769]
Model with surgery 0.39260.017 0.360.9 0.707 [0.641;0.774]
Model with HER2 0.39660.019 20.662.1 0.700 [0.631;0.769]
Model with mitotic index 0.36760.023 6.763.2 0.738 [0.674;0.802]
Model with genomic signature 0.34260.019 13.163.6 0.775 [0.718;0.832]
All models are estimated taking into account Adjuvant! Prediction as an offset. Data are presented as the mean 6 standard error.
doi:10.1371/journal.pone.0027446.t007
Figure 3. Difference (D) between observed outcome and Adjuvant! Online prediction in three other major confirmation studies
[9,10,11].
doi:10.1371/journal.pone.0027446.g003
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